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2ABSTRACT:
The six-minute walk test (6-MWT) is widely used to assess functional status in patients
with chronic heart failure (CHF). The aims of the present study were: (1) to compare
metabolic gas exchange during the 6-MWT in older patients with left ventricular systolic
dysfunction (LVSD) and in breathless patients with no major structural heart disease
(MSHD); (2) to determine the exercise intensity of the 6-MWT relative to peak oxygen
uptake; (3) to establish the accuracy and reproducibility of the Metamax 3B
ergospirometer during an incremental workload. Twenty four older patients with LVSD
(19 male; age 76 ± 5 years; BMI 27 ± 4), and 18 patients with no MSHD (12 male; age 75
± 8 years; BMI 27 ± 4) attended on consecutive days at the same time. Patients
completed a 6-MWT with metabolic gas exchange measurements using the Metamax 3B
portable ergospirometer, and an incremental cycle ergometry test using both the
Metamax 3B and Oxycon Pro metabolic cart. Patients returned and performed a second
6-MWT and an incremental treadmill test, metabolic gas exchange was measured with the
Metamax 3B. In patients with LVSD, the 6-MWT was performed at a higher fraction of
maximal exercise capacity (P=0.02).The 6-MWT was performed below the anaerobic
threshold in patients with LVSD (83%) and in patients with no MSHD (61%). The
Metamax 3B showed satisfactory to high accuracy at 10W and 20W in patients with
LVSD (r =0.77-0.97, P<0.05), and no MSHD (r =0.76-0.94, P<0.05). Metabolic gas
exchange variables measured during the 6-MWT showed satisfactory to high day-to-day
reproducibility in patients with LVSD (ICC=0.75-0.98), but a higher variability was
evident in participants with no MSHD (ICC=0.62-0.97). The Metamax 3B portable
ergospirometer is an accurate and reproducible device during submaximal, fixed rate
exercise in older patients with LVSD and no MSHD. In elderly patients with LVSD and
no MSHD, the 6-MWT should not be considered a maximal test of exercise capacity but
rather a test of submaximal exercise performance. Our study demonstrates that the 6-
MWT takes place at a higher proportion of peak oxygen uptake in patients with LVSD
compared to those with no MSHD, and may be one reason why fatigue is a more
prominent symptom in these patients.
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3INTRODUCTION:
Left ventricular systolic dysfunction (LVSD) is a common and serious complication of
myocardial infarction that leads to greatly increased risk of sudden death and heart failure
(HF) [6]. Left ventricular systolic dysfunction and heart failure are not synonymous [18].
Some patients will suffer major left ventricular damage and yet be asymptomatic. Left
ventricular systolic dysfunction can be measured fairly objectively but signs and
symptoms of HF are subjective and the threshold for diagnosis will vary widely among
clinicians. The six-minute walk test (6-MWT) is widely used to assess functional status in
patients with LVSD and HF, and is reproducible and sensitive to changes in quality of
life [13, 20, 26]. It is a self-paced test, and exercise intensity mimics activities of daily
living [4, 29]. However, some reports indicate that its performance may require an
exercise intensity above the anaerobic threshold in patients with HF, in contrast to
healthy participants [7, 8]. Recently, we showed [14] that clinical predictors of poor 6-
MWT performance were similar in patients with LVSD and in patients referred with
symptoms of breathlessness, but diagnosed with no major structural heart disease
(MSHD). No previous studies have compared metabolic gas exchange measurements
during the 6-MWT in these two groups of patients.
Automated metabolic gas analysers provide a broader range of data than traditional
Douglas bag methods, and these systems can be used as a ‘gold standard’ criterion in
validation studies [12, 19]. The Oxycon Pro stationary metabolic cart (Viasys, PA, USA)
has been previously validated against the Douglas bag system for metabolic
measurements of oxygen uptake collected in low to high exercise intensity domains [5, 9,
28]. However, a difficulty in assessing the oxygen cost of the 6-MWT is the need for a
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majority of previous studies have used the Cosmed portable breath-by-breath system
(Cosmed, Rome, Italy) to collect metabolic gas exchange measurements [7, 8, 10, 17, 29].
The Cortex Metamax I and II portable ergospirometers have been validated during low
and moderate intensity exercise in healthy, younger volunteers with results not differing
substantially from Douglas bag methods [19, 22] and stationary metabolic carts [23, 24].
Only one previous investigation has shown that data from the Cortex Metamax I device
is reproducible in young, healthy participants [12], but the Metamax 3B model has yet to
be validated during exercise with incremental workload in older patients with LVSD or in
patients with signs of breathlessness but without MSHD. The aims of the present study
were: (1) to compare metabolic gas exchange during the 6-MWT in elderly patients with
LVSD and in breathless patients with no MSHD; (2) to determine the exercise intensity
of the 6-MWT relative to peak oxygen uptake; (3) to establish the accuracy and
reproducibility of the Metamax 3B ergospirometer during incremental exercise in these
patient groups.
METHODS:
The Hull and East Riding ethics committee approved the study, and all patients provided
written informed consent for participation. Patients were recruited from the local
community heart failure clinic. Eighty three percent of patients had heart failure of
ischaemic aetiology, and all had suffered from the condition for at least 6 months before
the study. Patients were studied when they were clinically stable, without any changes in
medication during the previous three months. Heart failure was defined in accordance
with National Institute for Clinical Excellence Guidelines [25] and the European Society
of Cardiology [27]. Left ventricular function was determined from 2D-echocardiography
5or magnetic resonance imaging. Echocardiography was carried out by one of three
trained operators. Left ventricular function was assessed by visual estimation on a scale
of normal, mild, moderate, and severe impairment, and was assessed by a second
operator blind to the assessment of the first; where there was disagreement on the
severity of LV dysfunction, the echocardiogram was reviewed jointly with the third
operator and a consensus reached. Left ventricular ejection fraction (LVEF) was
calculated using the Simpson’s formula from measurements of end-diastolic and end-
systolic volumes on apical 2D views, following the guidelines of Schiller and colleagues
[30], and LVSD was diagnosed if LVEF was ≤ 40%. When the echocardiogram was of
low quality, patients underwent a cardiac magnetic resonance (CMR) scan to determine
left ventricular volume and function.
Patients with co-morbidities including chronic obstructive pulmonary disease (COPD)
(FEV1 >70% predicted), osteoarthritis, diabetes mellitus, and hypertension were
included in the study. Severe renal impairment was diagnosed as estimated GFR <30
mL·min·1.73m2. There was a history of tobacco use in 83% of patients, although only
6% were current tobacco users. Patients were excluded if they were unable to walk
without assistance from another person (not including mobility aids). For comparative
purposes, an age-matched control group of participants with no MSHD was included.
These participants were referred to the clinic with symptoms of breathlessness, but were
not diagnosed with heart failure following investigation; the same inclusion/exclusion
criteria applied. All participants were invited to attend on consecutive days at the same
time; on Day 1, patients performed a 6-MWT and a submaximal, fixed rate exercise test
on a cycle ergometer. On Day 2, patients performed a second 6-MWT, and a symptom-
limited graded exercise test to volitional exhaustion on a treadmill.
6Day 1
Patients underwent clinical history and physical examination, together with ECG, and
echocardiogram. The 6-MWT was conducted following a standardised protocol [1, 11]. A
15 m flat, obstacle-free corridor, with chairs placed at either end was used. Patients were
instructed to walk as far as possible, turning 180º every 15 m in the allotted time of six
minutes. The Metamax 3B portable ergospirometer (Cortex, Leipzig, Germany) was used
to measure metabolic gas exchange. The device requires the patient to wear a tightly
fitting facemask to collect exhaled air. A turbine is connected to the facemask to measure
respiratory flow. The power source and expired gas analysers are worn in a harness fitted
to the chest. The oxygen and carbon dioxide analyser use an electro-chemical cell and
infrared absorpimetry system. The radio transmission range is 1000m and data are
continuously transmitted to the receiver. The total weight of the device is 330g. Before
patient assessment, the device was calibrated against gases of known concentration and
volume.
During the 6-MWT, patients were able to rest, if needed, and time remaining was called
every second minute [3]. Patients walked unaccompanied so as not to influence walking
speed. After six minutes, patients were instructed to stop and total distance covered was
calculated to the nearest metre. Standardised verbal encouragement was given to patients
after 2 min and 4 min. A rest period of between 30-45 min was administered between the
end of the 6-MWT and the start of the cycle ergometer test.
After an initial familiarisation test, participants performed an unloaded warm-up stage on
a cycle ergometer for 3 min (Rehcor, Cardiokinetics, Salford, UK). Participants
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stages was chosen to elicit steady state exercise responses. In randomised order,
participants had metabolic gas exchange measured with either the Metamax 3B or
Oxycon Pro metabolic cart (VIASYS, PA, USA) for 4 min. The devices were changed
after 4 minutes. Initially, the incumbent device was paused, and the mouthpiece
connected to the facemask was detached and replaced with the mouthpiece from the
second ergospirometer. The exchange took less than 10 seconds, and the final minute of
activity was measured immediately following the change of mouthpieces and activation
of the new analyser. For comparative purposes, oxygen uptake (
.
V O2), carbon dioxide
production (
.
V CO2), minute ventilation (
.
V E), and the respiratory exchange ratio (RER)
were averaged over the final 30s of each workload i.e. 3 min 30 sec until 4 min of
exercise (1st analyser), and 4 min 30 sec until 5 min of exercise (2nd analyser).
Day 2
The following day, participants returned and repeated the 6-MWT following the same
protocol. After a 1 hour rest period, participants then underwent a symptom-limited,
treadmill-based maximal exercise test to volitional exhaustion using the Bruce protocol
modified by the addition of a Stage 0 with 1.0 mph and 5% gradient. Metabolic gas
exchange measurements were made by the Metamax 3B portable ergospirometer. Peak
oxygen uptake (p
.
V O2), peak carbon dioxide production (p
.
V CO2), and peak minute
ventilation (p
.
V E) were measured during the final 30s of the test. Anaerobic threshold
(AT) was calculated by the V-slope method [2], and was assessed by a second operator
blind to the assessment of the first; where there was disagreement, the AT was reviewed
jointly by a third operator and a consensus reached.
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Data were analysed using SPSS statistical software for Windows version 11.5 (SPSS Inc,
Chicago, Illinois, USA). To assess reproducibility, intraclass correlation coefficients (ICC)
with 95% confidence intervals (CIs) were calculated. An ICC of ≥0.75 has been
recommended as displaying satisfactory agreement when studying groups of patients, so
we used this threshold in our study [13]. Before assessing the accuracy of the
ergospirometer, we ran a Kolmogorov-Smirov test which showed that the normality
assumption had been violated; consequently, we used the Spearman’s correlation
coefficient. Paired samples t-tests were used to identify group differences; this test
statistic was selected as data were normally distributed. Data are presented as mean ±
SD, all tests were two-sided, and P<0.05 was taken as being statistically significant.
RESULTS:
Twenty four patients with LVSD (19 male; 76 ± 5 years; BMI 27 ± 4; LVEF 36 ± 5%),
and 18 participants with no MSHD (12 male; 75 ± 8 years; BMI 27 ± 4; LVEF 58 ±
14%) took part in the study (Table 1). No 6-MWT was prematurely stopped, and only
one patient stopped to rest. Five patients in the LVSD group and 3 in the no MSHD
group failed to attempt 30W during the fixed rate cycle ergometer test due to
breathlessness or leg fatigue. Twenty two percent of echocardiograms were classified as
low quality, and in these cases, CMR scans were performed to determine left ventricular
volume and function.
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Peak oxygen uptake and anaerobic threshold values were obtained from the incremental
treadmill test. Patients with no MSHD had a higher peak oxygen uptake (P=0.04) and
AT (P=0.02) than patients with LVSD (Table 2). Conversely, patients with LVSD have a
higher VE/VCO2 slope (P=0.001). Oxygen uptake requirements for the 6-MWT were
not different between groups, which shows that
.
V O2/metre was lower in controls.
Oxygen consumption increased during the 6-MWT in both groups (P<0.05) (Figure 1).
The AT was higher than mean
.
V O2 values during the 6-MWT (P<0.05) (Figure 2). In all
patients with LVSD, the 6-MWT was performed at a higher proportion of maximal
exercise capacity compared with controls (P=0.02). The AT in relation to p
.
V O2 was
significantly higher in patients with LVSD (89 ± 8% v 79 ± 5%, P=0.04), and
.
V O2
during the 6-MWT as a proportion of the AT was higher in patients with LVSD (83 ±
16% v 61 ± 17%, P=0.001). Patients with no MSHD walked significantly further
(P=0.03) than those with LVSD (Table 3).
Accuracy and reproducibility of the Metamax 3B ergospirometer
Data from the Metamax 3B was accurate (r =0.87-0.97, P<0.05) and reproducible
(ICC=0.78-0.98) at 10W and 20W in patients with LVSD, and in patients without
MSHD (r =0.76-0.94, P<0.05; ICC=0.76-0.98) (Figure 3). At 30W, we did not measure
accuracy and reproducibility due to drop-out in both groups.
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Day-to-day reproducibility of the 6-MWT
The 6-MWT showed high day-to-day reproducibility in patients with LVSD (ICC=0.98),
and those with no MSHD (ICC=0.97). Reproducibility of metabolic gas exchange
variables was ICC=0.75-0.98 in patients with LVSD, while in participants without
MSHD reproducibility was ICC=0.62-0.97 (Table 3).
DISCUSSION:
Metabolic gas exchange during the 6-MWT
The current study shows that patients with LVSD and no MSHD perform the 6-MWT
below the AT; and thus, the 6-MWT is a submaximal test. Patients with LVSD
performed the 6-MWT at a higher relative exercise intensity (83% of AT), than those
with no MSHD (61% of AT). The mean respiratory exchange ratio was <1.00 during the
6-MWT in both patient groups, also indicating a submaximal test. Five previous studies
have examined the relative exercise intensity of the 6-MWT in a similar cohort of
patients [7, 8, 10, 17, 29]. Only one of these studies [27] reported that the 6-MWT was a
submaximal test in patients with HF. Gayda and colleagues [10] recruited 25 patients
with coronary artery disease following a cardiac event, mean age 60 ± 10 years. Patients
with a LVEF of >35% were included, with 15 of 25 patients having an LVEF >65%.
Patients performed the maximal exercise test on a cycle ergometer, and then performed a
6-MWT using the Cosmed K2 portable ergospirometer. Gayda et al [10] reported that
oxygen uptake during the 6-MWT was higher, although not significantly than the AT. It
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was not clear from the study why patients were asked to perform the maximal exercise
test on a cycle ergometer, which does not mimic the movement pattern of the 6-MWT.
Secondly, patients did not perform the maximal exercise test with the same
ergospirometer, which is likely to have implications for the validity and reproducibility of
the data.
Kervio and co-workers [17] recruited 12 patients with HF (9 male, mean age 64 ± 6
years, LVEF = 30 ± 8%) treated with conventional medication. 12 patients with HF (10
male, 66 ± 6 years, LVEF 24 ± 9%) receiving conventional drug therapy plus cardiac
pacing were also included. Patients were excluded if they were limited because of co-
morbidities including angina, neurological impairments, and orthopaedic limitations
(arthritis, claudication). All patients were aged between 55-75 years and categorised in
NYHA functional classes II and III, performed a symptom-limited treadmill test using
the Cosmed K4 portable ergospirometer and two 6-MWTs (corridor length =18m) using
the same device. During the 6-MWT, patients were provided with verbal encouragement
every 30 seconds. Oxygen uptake values during the 6-MWT were significantly higher
than the AT (P<0.01), and consequently the authors reported that the 6-MWT was a near
maximal test (90% of peak oxygen uptake). These data conflict with findings in the
current study. These differences probably reflect different clinical, demographic and
methodological characteristics between the two studies. The current study recruited older
patients, inclusion criteria were less restrictive, 6-MWT corridor length was shorter, and
verbal encouragement was less frequent. Elderly patients with LVSD and no MSHD
perform the 6-MWT below the AT following our protocol and using a corridor length of
15m. These data should not be extrapolated to other populations, or to research groups
using a more aggressive 6-MWT coaching approach. Our approach is justified in an
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elderly, chronic disease population and follows the established guidelines of the
American Thoracic Society [1].
We found that there was a gradual increase in oxygen uptake during the 6-MWT. These
data suggest that the metabolic demands of the 6-MWT increase as the test duration
continues, a finding that has been shown previously in patients with coronary artery
disease [10]. However, our data show that even in the final minute of the 6-MWT, the
oxygen uptake metabolic demands remain below the AT.
Day-to-day reproducibility of the 6-MWT
The distance walked during the 6-MWT showed high day-to-day reproducibility in
patients with LVSD (ICC=0.98), and those with no MSHD (ICC=0.97). Metabolic gas
exchange variables were highly reproducibility in patients with LVSD (ICC=0.75-0.98),
but a greater degree of variability was seen in participants with no MSHD (ICC=0.62-
0.97). Kervio and colleagues [15] showed similar reproducibility data for patients with
HF who performed two 6-MWT’s on the same day (am and pm). They reported an
ICC=0.98-0.99 for 6-MWT distance, and an ICC=0.97-0.99 for mean oxygen uptake
during the 6-MWT, in patients with HF under optimal drug therapy and optimal drug
therapy plus cardiac pacing. Our study shows that the 6-MWT produces higher day-to-
day reproducibility for metabolic gas exchange variables in patients with LVSD than in
patients with no MSHD. It is difficult to speculate on explanations for this observation.
We have previously shown that the reproducibility of the 6-MWT over 12 months is
satisfactory (ICC = 0.80, 95% CI=0.69-0.87) in 74 patients with HF showing no change
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in symptoms [9]. There is a small decline in reproducibility over 12 months in patients
with HF.
Accuracy and reproducibility of the Metamax 3B ergospirometer
In patients with HF, the Cosmed system (Cosmed, Rome, Italy) has been previously used
to collect metabolic gas exchange data [7, 8, 10, 17, 29]. Data collected from the portable
Metamax I and II systems have shown a strong correlation with data collected from
Douglas bags [19, 22] and stationary metabolic carts [23, 24] in healthy, younger adults
during low to high intensity incremental exercise. The Metamax 3B model had yet to be
validated during exercise with incremental workload in older patients with LVSD or in
patients with symptoms of breathlessness but without MSHD. We compared the
Metamax 3B portable device against the Oxycon stationary metabolic cart, which has
been previously validated against Douglas bag systems [5, 9, 28] and recommended as a
‘gold standard’ criterion measure [12, 21]. Stationary Oxycon systems have been used
previously in HF trials [e.g. 14, 16].
We found satisfactory accuracy and reproducibility in the Metamax 3B in older patients
with and without LVSD. Accuracy and reproducibility was not calculated at 30W due to
patient drop-out as a result of breathlessness and leg pain. Many of these patients had a
peak oxygen uptake of <14 mL·kg-1·min-1, and 30W of exercise was an excessively high
relative intensity. To identify whether an upward drift in oxygen uptake due to the ‘slow
component’ occurred during the transition phases of the submaximal cycle ergometry
test we found that the mean oxygen uptake value was 5.8 mL·kg-1·min-1 after 4 min, and
5.9 mL·kg-1·min-1 after 5 min at 10W. At 20W, mean oxygen uptake value was 6.9 mL·kg-
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1·min-1 after 4 min, and 6.9 mL·kg-1·min-1 after 5 min in patients with LVSD. The same
trend was noted in patients with no MSHD suggesting that an upward drift in oxygen
uptake due to the ‘slow component’ was not a factor in the current study.
Studies reporting accuracy and reproducibility data for portable Cortex Metamax systems
are scarce, we could only find one study [23], which showed that the Metamax I is highly
reproducible (ICC=0.98) during fixed rate, ramped cycle ergometry exercise in healthy,
young men. Our findings show that the Metamax 3B portable ergospirometer can be
used confidently to perform metabolic gas exchange measurements in patients with
LVSD and no MSHD at submaximal workloads (10-20W).
CONCLUSION
The Metamax 3B portable ergospirometer is accurate and reproducible device during
submaximal, fixed rate exercise in elderly patients with LVSD and no MSHD. The 6-
MWT shows very good day-to-day reproducibility in these patients. However, data
should not be extrapolated to other populations, or to groups using a more aggressive 6-
MWT coaching approach. In elderly patients with LVSD and no MSHD, the 6-MWT
should not be considered a maximal test of exercise capacity but rather a test of
submaximal exercise performance. Our study demonstrates that the 6-MWT takes place
at a higher proportion of peak oxygen uptake in patients with LVSD compared to those
with no MSHD, and may be one reason why fatigue is a more prominent symptom in
these patients.
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